What Scendea does

Scendea is an international product development, regulatory, and compliance consulting group headquartered in Bishop's Stortford, United Kingdom, with operational offices in Washington DC, San Diego, Amsterdam, and Brisbane. Founded in 2004 as a management buyout of the product development and regulatory consulting function of a clinical research organisation, the firm serves pharmaceutical and biotechnology companies ranging from academic spin-outs to large pharma, alongside investors in life sciences. Across more than 20 years of operation, Scendea reports involvement in over 1,000 development programmes covering more than 100 indications and 25 therapeutic areas, with particular depth in oncology, infectious disease, respiratory, and rare/orphan indications. The firm holds B Corp certification and received the King's Award for Enterprise for International Trade in 2024.

The company's offering is organised into four core service pillars — Non-Clinical (toxicology and safety pharmacology consulting), CMC (chemistry, manufacturing, and controls), Clinical (clinical development plans, regulatory submissions including IND, CTA, NDA, BLA, MAA, and programme management), and Regulatory (global strategy for US, EU, and UK) — supported by a dedicated Compliance division delivering GxP Audits, CRO/CDMO Oversight, Quality Management System support, and GxP Training. There is no proprietary software platform, algorithms, or hardware product; the underlying "technology" is the institutional expertise of a bench of senior consultants that includes a former FDA Chief Pediatrician, ex-FDA pharmaceutical chemists and investigative analysts, former MHRA Senior Medical and Non-Clinical Assessors, a former UK GCP Inspector, and ex-executives from PPD, GSK, AstraZeneca, Johnson & Johnson, Amgen, Lonza, and Daiichi Sankyo. The firm's CMO, Dr Maria Beatrice Panico, received the 2023 TOPRA Award for Regulatory Excellence (Lifetime Achievement).

Scendea monetises through three engagement models — Ad Hoc (pay-as-you-go), Project Based (fixed scope, defined budget), and Partial FTE (dedicated expert allocation over a flexible period) — with all pricing quote-based and not publicly disclosed. The go-to-market motion is enterprise field sales led by senior consultants, complemented by thought-leadership content (regulatory intelligence blog, whitepapers), conference attendance (BIO International, DIA, LSX Congress, Bio Connections Australia, Cell & Gene Meeting on the Mesa), LinkedIn engagement, and partner referrals. Strategic alliances with Japan's CUES Consulting (announced August 2024), pharmacovigilance provider Signal, and joint thought-leadership with ERBC and FGK extend geographic reach into Japan and broaden the integrated service offering.

Name

Scendea

Legal name

Scendea Ltd

Website

https://scendea.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Scendea is a UK-headquartered product development, regulatory, and compliance consulting group serving pharmaceutical, biotech, academic spin-out, and investor clients globally, with offices in the US, Netherlands, and Australia and expertise across 25 therapeutic areas.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory & Product Development Consulting

NAICS

Other Scientific and Technical Consulting Services (54169), Other Management Consulting Services (541618), Scientific Research and Development Services (5417)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industries

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Regulatory affairs consulting
• Pharmaceutical product development
• Biotech regulatory strategy
• GxP compliance auditing
• Clinical development consulting

Headquarters

HQ city

Bishops Strotford

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Regulatory & Product Development Consulting Services: Scendea generates revenue by providing consulting services across Non-Clinical, CMC, Clinical, Regulatory, and Compliance. Engagement models include Ad Hoc (pay-as-you-go), Project Based (fixed-scope), and Partial FTE (dedicated expert allocation). Services are delivered by a global team of experienced consultants to pharmaceutical and biotech clients worldwide.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Scendea is an international product development, regulatory, and compliance consulting firm that delivers scientific, regulatory, and quality consulting services to pharmaceutical and biotechnology companies. Its core offering spans Non-Clinical (toxicology/safety), CMC (chemistry, manufacturing and controls), Clinical (development, submissions, programme management), Regulatory (global strategy for US/EU/UK), and Compliance (GxP audits, CRO/CDMO oversight, QMS support, GxP training) services, delivered via Ad Hoc, Project-Based, and Partial FTE engagement models by former regulatory agency assessors and pharma executives.

Product overview

Scendea is a consulting group offering a portfolio of specialised services rather than a unified software product. The core service suite spans four interconnected areas: Non-Clinical Services (toxicology and safety assessment consulting), CMC Services (chemistry, manufacturing and controls), Clinical Services (clinical development, regulatory submissions and programme management), and Regulatory Services (global regulatory strategy for US, EU and UK markets). These are supported by a dedicated Compliance division delivering four service modules: GxP Audits (GLP, GCP, GMP, GVP audit programmes), CRO & CDMO Oversight (contract research and manufacturing organisation governance), Quality Management System (QMS) Support (gap analysis, QMS development, investigations), and GxP Training (tailored compliance training). Clients can engage via Ad Hoc consulting, Project-Based engagements with defined scope and budget, or the Partial FTE model for dedicated expert allocation over a flexible period.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Clinical Services Non-clinical scientific and regulatory consulting covering toxicology, safety pharmacology, and regulatory affairs to support pre-clinical development programmes for pharmaceutical and biotechnology clients.
• CMC Services Chemistry, Manufacturing and Controls consulting providing global CMC technical and regulatory advice from early-stage development through to marketing authorisation and post-marketing phases for pharmaceutical and biotechnology clients.
• Clinical Services Clinical development and operational support including Clinical Development Plan creation, gap analysis, clinical study reports, protocol development, regulatory submissions (IND, CTA, NDA, BLA, MAA), agency interactions, and programme/project management.
• Regulatory Services Global regulatory strategy consulting for US, EU and UK markets covering designations, Target Product Profile development, pre-submission interactions, and procedural management for marketing authorisation.
• GxP Audits Comprehensive GxP audit services covering GLP, GCP, GMP and GVP across systems, studies and vendors, including inspection readiness support and issue resolution for pharmaceutical and biotech clients.
• CRO & CDMO Oversight Expert oversight services for non-clinical and clinical Contract Research Organisations and Contract Development and Manufacturing Organisations to maintain quality, safety and compliance throughout product development.
• Quality Management System (QMS) Support Practical and scalable support to develop, assess and maintain compliant and effective Quality Management Systems, covering gap analysis, QMS development, and investigations and root cause analysis.
• GxP Training Tailored GxP training across GCP, GLP, GMP and GVP frameworks, delivered onsite or remotely to support compliance, internal capability development and inspection readiness for pharmaceutical and biotech clients.
• Partial FTE Solution Flexible engagement model providing access to Scendea's expert consultants for a dedicated period, allowing clients to integrate specialist regulatory and product development expertise without long-term commitments; more cost-effective than full-time hires.

Quantifiable outcome

• Over 1,000 development programmes supported
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• CUES ConsultingcoreStrategic or Co-development Partner · 27 August 2024Scendea announced a strategic partnership with CUES Consulting in August 2024. CUES Consulting specialises in Japanese regulatory affairs, safety management, and post-marketing surveillance. Together, the two firms assist clients seeking Japanese regulatory approval for their medicinal products, providing comprehensive support from product development through to market introduction in Japan. The partnership extends Scendea's geographic reach and regulatory expertise into the Japanese market.
• Signal (Pharmacovigilance Partner)coreStrategic or Co-development PartnerScendea's GVP (Good Pharmacovigilance Practice) services are delivered by its pharmacovigilance partner, Signal. This partnership enables Scendea to provide clients with reliable, expert pharmacovigilance support in line with global regulatory requirements, complementing Scendea's core regulatory and compliance consulting services.
• ERBC (European Regulatory & Biology Consulting)minorStrategic or Co-development PartnerScendea collaborated with ERBC on a joint whitepaper titled 'Lead Optimisation & Drug-Induced Cardiotoxicity'. Scendea authors Dr Erik Doevendans and Ellen Wilkinson worked alongside ERBC authors Pascal Champeroux and Raafat Fares. This collaboration produces thought leadership content combining Scendea's regulatory expertise with ERBC's non-clinical/cardiotoxicology specialisation.
• FGK (Represented in EU CTR Whitepaper)minorStrategic or Co-development PartnerScendea collaborated with FGK (a German regulatory consultancy) on a whitepaper titled 'Clinical Trial Regulation: A New Chapter for EU Clinical Trials'. Authored by Scendea Senior Consultant Amy Cooke, Principal Consultant Dr Maria Beatrice Panico, and FGK's Director of Regulatory Affairs Dr Uwe Kramer. This joint publication positions both firms as thought leaders in EU Clinical Trials Regulation.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• CUES Consulting: Tokyo-based regulatory affairs and pharmacovigilance consultancy. Now a Scendea strategic partner, but historically a peer in the Japanese regulatory services market for Western biotechs — direct overlap on PMDA-side regulatory work.
• Voisin Consulting Life Sciences: Paris- and US-headquartered boutique regulatory and product development consultancy serving pharma and biotech with regulatory strategy, CMC, and clinical development services. Closely comparable to Scendea in service mix, boutique scale, and global delivery model.
• FGK Representative Service: Munich-based regulatory consultancy and EU/UK/EEA MAH representative. Aligned with Scendea's European regulatory offering; the two firms have co-authored EU CTR thought leadership, confirming direct competitive and peer overlap.
• NDA Group: Sweden-based regulatory and product development consultancy with strong CMC, clinical, and regulatory affairs offerings to pharma and biotech. Comparable mid-size boutique competitor with similar global footprint and ex-regulator talent base.
• ProPharma Group: Global regulatory, compliance, and pharmacovigilance consultancy (recently acquired by AmerisourceBergen). Highly comparable in mid-large regulatory consulting scale with strong GxP audit and quality services portfolio.
• ERBC (European Regulatory & Biology Consulting): European non-clinical and regulatory consulting group with deep toxicology, safety pharmacology, and CMC capabilities. Comparable in non-clinical services portfolio and regulatory navigation offerings.
• Diamond Pharma Services: UK-based regulatory affairs and pharmacovigilance consultancy supporting pharma and biotech. Overlapping services (regulatory strategy, GxP compliance, PV) and similar boutique positioning; Paul Cronin previously held senior roles here.
• ERA Consulting (now Pharmalex): Regulatory and product development consultancy specializing in biologics, biosimilars, ATMPs, and CMC — comparable in scope and therapeutic-area depth to Scendea. Paul Cronin (Scendea Director) previously held senior roles at ERA, illustrating direct talent overlap.

Broad incumbents

• Parexel International: Top-5 global CRO offering comprehensive regulatory, clinical, CMC, and post-marketing services to large pharma and biotech. Overlaps with Scendea on regulatory strategy, but operates at vastly greater scale and as part of a full-service delivery platform.
• ICON plc: Global CRO with substantial regulatory and product development consulting practices (post-PRA Health Sciences). Competes with Scendea for biotech regulatory work but offers a far broader clinical and lab services portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/scendea
• LinkedInlinkedin.com/company/scendea

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scendea